Epstein-Barr virus BZLF1 protein (BZLF1) (BZLF1)

The Epstein-Barr virus (EBV) BZLF1 protein, also known as Zta or ZEBRA, is a master regulatory transcription factor that initiates the switch from latent to lytic infection (UniProt: P03206). It belongs to the basic leucine zipper (bZIP) family and functions by binding to Z-response elements (ZREs) on the viral genome, including its own promoter and the promoters of early lytic genes (PMID: 15141007). BZLF1 is crucial for the pathogenesis of EBV-associated malignancies, such as Burkitt lymphoma and nasopharyngeal carcinoma, where it is typically silenced during latency but can be reactivated to drive viral replication (PMID: 25143474). In drug development, BZLF1 is targeted through two primary strategies: inhibition of its expression or activity to prevent viral reactivation, and "lytic induction therapy," which uses agents like HDAC inhibitors (e.g., Vorinostat) to trigger BZLF1 expression and sensitize latent cells to antiviral drugs (PMID: 25143474). While valpromide has been identified as an inhibitor of BZLF1 expression, the therapeutic challenge remains the risk of systemic viral spread during induction-based treatments (PMID: 11160736).

Other names

ZtaZEBRAEB1ZBZLF1 transactivatorImmediate-early protein BZLF1

Modulation of the viral lytic-latent switch through transcriptional activation or inhibition of BZLF1-mediated gene expression.